Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Analytical performance of the Hologic Aptima HBV Quant Assay and the COBAS Ampliprep/COBAS TaqMan HBV test v2.0 for the quantification of HBV DNA in plasma samples

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The challenges of defining sample adequacy in an era of HPV based cervical screening

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Aseptic meningitis outbreak associated with echovirus 4 in Northern Europe in 2013-2014

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Hepatitis B virus elimination status and strategies in circumpolar countries, 2020

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prevalence and association with birth outcomes of low Vitamin D levels among pregnant women living with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Quantification of HBV DNA is used for initiating and monitoring antiviral treatment. Analytical test performance consequently impacts treatment decisions.

OBJECTIVES: To compare the analytical performance of the Aptima HBV Quant Assay (Aptima) and the COBAS Ampliprep/COBAS TaqMan HBV Test v2.0 (CAPCTMv2) for the quantification of HBV DNA in plasma samples.

STUDY DESIGN: The performance of the two tests was compared on 129 prospective plasma samples, and on 63 archived plasma samples of which 53 were genotyped. Linearity of the two assays was assessed on dilutions series of three clinical samples (Genotype B, C, and D).

RESULTS: Bland-Altman analysis of 120 clinical samples, which quantified in both tests, showed an average quantification bias (Aptima - CAPCTMv2) of -0.19 Log IU/mL (SD: 0.33 Log IU/mL). A single sample quantified more than three standard deviations higher in Aptima than in CAPCTMv2. Only minor differences were observed between genotype A (N = 4; average difference -0.01 Log IU/mL), B (N = 8; -0.13 Log IU/mL), C (N = 8; -0.31 Log IU/mL), D (N = 25; -0.22 Log IU/mL), and E (N = 7; -0.03 Log IU/mL). Deming regression showed that the two tests were excellently correlated (slope of the regression line 1.03; 95% CI: 0.998-1.068). Linearity of the tests was evaluated on dilution series and showed an excellent correlation of the two tests. Both tests were precise with %CV less than 3% for HBV DNA ≥3 Log IU/mL.

CONCLUSIONS: The Aptima and CAPCTMv2 tests are highly correlated, and both tests are useful for monitoring patients chronically infected with HBV.

OriginalsprogEngelsk
TidsskriftJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Vol/bind104
Sider (fra-til)83-88
ISSN1386-6532
DOI
StatusUdgivet - jun. 2018

ID: 54349811